Laleh Amiri‐Kordestani

Current Landscape of Immunotherapy in Breast Cancer

Sylvia Adams, Margaret E. Gatti‐Mays, Kevin Kalinsky et al. · JAMA Oncology · 2019 · 409 citations · Full text

Medicine, Immunology, Oncology +17

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu et al. · Clinical Cancer Research · 2014 · 345 citations

Medicine, Oncology, Pharmacology +17

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer Gao, Joyce Cheng, Erik Bloomquist et al. · The Lancet Oncology · 2019 · 297 citations

Medicine, Oncology, Pharmacology +17

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Sara M. Tolaney, Elizabeth Garrett‐Mayer, Julia White et al. · Journal of Clinical Oncology · 2021 · 221 citations · Full text

Medicine, Biostatistics, Oncology +13

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman et al. · Clinical Cancer Research · 2022 · 220 citations · Full text

Medicine, Oncology, Pharmacology +17